3 assets in Urethra Clear Cell Adenocarcinoma

Therapeutic assets addressing Urethra Clear Cell Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib Urethra Clear Cell Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Urethra Clear Cell Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Urethra Clear Cell Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)